Sanofi’s Sarclisa (isatuximab) has been approved by the Medicines and Healthcare product Regulatory Agency (MHRA) as part of a combination treatment for newly diagnosed multiple myeloma (MM).
The UK-wide Innovative Licensing and Access Pathway (ILAP) was first launched in 2021 to reduce the time to market for innovative medicines by offering drug developers a single platform to collaborate ...